Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration‐resistant prostate cancer

BACKGROUND: Despite multiple treatment advances for castration‐resistant prostate cancer (CRPC), there are currently no curative therapies and patients ultimately to succumb to the disease. Docetaxel (DTX) is the standard first‐line chemotherapy for patients with metastatic CRPC; however, drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilling, Amanda, Kim, Sahn‐Ho, Hwang, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298324/
https://www.ncbi.nlm.nih.gov/pubmed/34672379
http://dx.doi.org/10.1002/pros.24257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298324/
https://www.ncbi.nlm.nih.gov/pubmed/34672379
http://dx.doi.org/10.1002/pros.24257

Ejemplares similares